These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 18243516

  • 1. Effective treatment of neurogenic detrusor dysfunction by combined high-dosed antimuscarinics without increased side-effects.
    Amend B, Hennenlotter J, Schäfer T, Horstmann M, Stenzl A, Sievert KD.
    Eur Urol; 2008 May; 53(5):1021-8. PubMed ID: 18243516
    [Abstract] [Full Text] [Related]

  • 2. Neurogenic bladder treatment by doubling the recommended antimuscarinic dosage.
    Horstmann M, Schaefer T, Aguilar Y, Stenzl A, Sievert KD.
    Neurourol Urodyn; 2006 May; 25(5):441-5. PubMed ID: 16847942
    [Abstract] [Full Text] [Related]

  • 3. Tolterodine for overactive bladder: time to onset of action, preferred dosage, and 9-month follow-up.
    Atan A, Konety BR, Erickson JR, Yokoyama T, Kim DY, Chancellor MB.
    Tech Urol; 1999 Jun; 5(2):67-70. PubMed ID: 10458657
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of extended-release tolterodine for the treatment of neurogenic detrusor overactivity and/or low-compliance bladder.
    Watanabe M, Yamanishi T, Honda M, Sakakibara R, Uchiyama T, Yoshida K.
    Int J Urol; 2010 Nov; 17(11):931-6. PubMed ID: 20969642
    [Abstract] [Full Text] [Related]

  • 5. Long-term outcome of intravesical oxybutynin in children with detrusor-sphincter dyssynergia: with special reference to age-dependent parameters.
    Humblet M, Verpoorten C, Christiaens MH, Hirche H, Jansen K, Buyse G, van Gool JD.
    Neurourol Urodyn; 2015 Apr; 34(4):336-42. PubMed ID: 24436114
    [Abstract] [Full Text] [Related]

  • 6. Is there a synergistic effect of topical oestrogens when administered with antimuscarinics in the treatment of symptomatic detrusor overactivity?
    Serati M, Salvatore S, Uccella S, Cardozo L, Bolis P.
    Eur Urol; 2009 Mar; 55(3):713-9. PubMed ID: 18584946
    [Abstract] [Full Text] [Related]

  • 7. Combined antimuscarinics for treatment of neurogenic overactive bladder.
    Nardulli R, Losavio E, Ranieri M, Fiore P, Megna G, Bellomo RG, Cristella G, Megna M.
    Int J Immunopathol Pharmacol; 2012 Mar; 25(1 Suppl):35S-41S. PubMed ID: 22652160
    [Abstract] [Full Text] [Related]

  • 8. Antimuscarinic agents exhibit local inhibitory effects on muscarinic receptors in bladder-afferent pathways.
    Kim Y, Yoshimura N, Masuda H, de Miguel F, Chancellor MB.
    Urology; 2005 Feb; 65(2):238-42. PubMed ID: 15708029
    [Abstract] [Full Text] [Related]

  • 9. Long-term efficacy and safety of tolterodine in children with neurogenic detrusor overactivity.
    Reddy PP, Borgstein NG, Nijman RJ, Ellsworth PI.
    J Pediatr Urol; 2008 Dec; 4(6):428-33. PubMed ID: 19013412
    [Abstract] [Full Text] [Related]

  • 10. Effects on bladder function of combining elocalcitol and tolterodine in rats with outflow obstruction.
    Streng T, Andersson KE, Hedlund P, Gratzke C, Baroni E, D'Ambrosio D, Benigni F.
    BJU Int; 2012 Jul; 110(2 Pt 2):E125-31. PubMed ID: 22288904
    [Abstract] [Full Text] [Related]

  • 11. [High-dose trospium chloride in therapy of detrusor hyperreflexia].
    Madersbacher H, Stöhrer M, Richter R, Giannetti BM, Mürtz G.
    Urologe A; 1991 Jul; 30(4):260-3. PubMed ID: 1926674
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study.
    Kennelly MJ, Lemack GE, Foote JE, Trop CS.
    Urology; 2009 Oct; 74(4):741-5. PubMed ID: 19628264
    [Abstract] [Full Text] [Related]

  • 13. [Spasmex treatment of patients with hyperactive urinary bladder].
    Pushkar' DIu, Shchaveleva OB.
    Urologiia; 2003 Oct; (4):46-9. PubMed ID: 12942728
    [Abstract] [Full Text] [Related]

  • 14. [Trospium chloride (spasmex) in the treatment of lower urinary tract symptoms in patients with neurogenic hyperactive urinary bladder caused by vertebrogenic lesions].
    Mazo EB, Babanina GA.
    Urologiia; 2007 Oct; (3):15-9. PubMed ID: 17722614
    [Abstract] [Full Text] [Related]

  • 15. [Treatment of overactive bladder in older women increased doses of antimuscarinic drugs safe and effective alternative to existing methods].
    Kosilov KV, Loparev SA, Krasnykh MA, Kosilova LV.
    Adv Gerontol; 2014 Oct; 27(1):149-55. PubMed ID: 25051773
    [Abstract] [Full Text] [Related]

  • 16. [The use of intravesical oxybutynin hydrochloride in patients with neurogenic bladder managed by intermittent catheterization].
    Yokoyama O, Ishiura Y, Nakamura Y, Ohkawa M.
    Hinyokika Kiyo; 1995 Jul; 41(7):521-4. PubMed ID: 7668182
    [Abstract] [Full Text] [Related]

  • 17. Combined low-dose antimuscarinics for refractory detrusor overactivity in children.
    Fahmy A, Youssif M, Rhashad H, Mokhless I, Mahfouz W.
    J Pediatr Urol; 2016 Aug; 12(4):219.e1-5. PubMed ID: 27282551
    [Abstract] [Full Text] [Related]

  • 18. Long-term effects of repeated intradetrusor botulinum neurotoxin A injections on detrusor function in patients with neurogenic bladder dysfunction.
    Pannek J, Göcking K, Bersch U.
    BJU Int; 2009 Nov; 104(9):1246-50. PubMed ID: 19426192
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.